GlobalData on MSN
Tandem secures FDA approval for Control-IQ+ use in pregnancy
The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.
Tandem Diabetes Care (Nasdaq:TNDM) today announced FDA clearance for its automated insulin delivery technology for use in ...
The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
US FDA clears Tandem Diabetes Care’s Control-IQ+AID technology for use in pregnancy complicated type 1 diabetes mellitus: San Diego Wednesday, April 29, 2026, 16:00 Hrs [IST] Ta ...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...
Tandem Diabetes Care, Inc.’s TNDM flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company’s LLY Lyumjev (insulin ...
MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...
Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results